Peptide Database

Peptide NameSARS-CoV-S (1134-1185)

Function Ontology

Antimicrobial

Antiviral

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV

Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition

Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor

Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor

Standard StatusStandard

Sequence Length60 amino acids

Chemical FormulaC298H478N78O104

DescriptionStandard

        ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
    

Molecular Weight6817.44 Da

Isoelectric Point (pI)4.27

Net Charge (pH 7.0)-8.06

Net Charge (pH 7.4) -8.30

Charge Density (pH 7.0) -0.1343

GRAVY Index-0.56

Hydrophobic Moment 0.70

Boman Index-0.08

Instability Index34.07

Aliphatic Index 107.17

Aromaticity 0.0500

Extinction Coeff. Reduced 1490.00

Extinction Coeff. Oxidized 1490.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

TPSA 3000.64

LogP -30.16

H-bond Donors 98.0

H-bond Acceptors 97.0

Rotatable Bonds 239.0

Heavy Atoms 480.0

Ring Count 5.0

Amide Bonds 67.0

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0365494 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyFusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV Fusion inhibition

TargetSARS-CoV | 118 cells

Activity34±4 μM

MethodEC50

Half-LifeMammalian: 1 h; Yeast: 30 min; E. coli: >10 h

PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/

RECORD: Rec_0373302 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antimicrobial Antiviral

TargetSARS-CoV:inhibition of virus infection in Vero cells

Activity34±4 μM

MethodEC50

RECORD: Rec_0426327 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV Fusion inhibition

TargetSARS-CoV | Vero cells

Activity34±4 μM

MethodEC50

Half-LifeMammalian: 1 h; Yeast: 30 min; E. coli: >10 h

PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/

FIRST PREV 1 2

Showing 3 records on this page Ã‚Â· Page 2 of 2